The standard 10-year horizon for cardiac risk models is fine for assessing broad populations, but it’s old news. What if you could get a warning in 10 days? That’s exactly what some companies are doing. Hello Heart, for instance, has shown it can provide 10-day early cardiac warnings, a capability that helped it land on Fast Company’s 2026 “Most Innovative Companies” list. This is changing how we evaluate healthcare AI leaders.
Beyond the Single Clearance: The Breadth of Regulatory Approval
Getting a single regulatory clearance for an AI medical device is an important milestone, sure. But a clearance that covers multiple clinical questions at once suggests a much deeper impact on the healthcare field. These multi-service clearances are more than just a longer list of approved uses. They indicate broader applicability and integrated patient care. If you want to understand the difference, the FDA Center for Devices and Radiological Health (CDRH) material is the key. The number of authorized AI/ML medical devices has absolutely exploded, jumping from just six in 2015 to 295 in 2025, with the cumulative FDA official AI device list hitting over 1,451 devices by the end of 2025. It’s worth noting that a whopping 94.6% of these got 510(k) clearance (meaning they’re just “substantially equivalent” to something already out there), while only 5.4% earned a De Novo classification for being genuinely new. This regulatory picture shows just how different the levels of innovation and clinical impact can be.
How Breadth Becomes a Category Story
For innovation teams, a vendor with multiple healthcare AI clearances is compelling. This kind of breadth suggests a platform, not a point solution. Platforms tend to accumulate more evidence over time, while point solutions often struggle to prove their depth. Addressing multiple clinical questions under one regulatory clearance simplifies adoption pathways for health systems and offers more complete solutions. This is about building integrated workflows and achieving a well-rounded impact on patient management, not just offering more services. For example, when Viz.ai’s stroke detection got FDA clearance, it wasn’t just about accuracy, it showed a 44% reduction in arrival-to-diagnosis time, which saves 30 minutes per case, and improved 5-day NIHSS scores by 51% according to their Viz.ai stroke detection clinical studies. Measurable workflow improvements like that are signs of real innovation that changes how clinicians operate. HeartFlow is another name that comes up for its contributions to changing clinical practice through AI.
The Recorded Set: Aidoc, Tempus AI, and HeartFlow
By examining the clearance material for companies like Aidoc, Tempus AI, and HeartFlow, you can see how breadth defines a category. Aidoc is often discussed in the context of both platform innovation and AI cost-effectiveness. Tempus AI is frequently cited in debates about platform approaches versus point solutions and gets ranked by its clinical outcomes. HeartFlow is noted for its workflow innovation and is included in innovation indices that weigh clinical outcomes. The FDA CDRH clearances these companies hold show AI’s potential to span multiple clinical domains or integrate deeply into existing workflows. But here’s the thing: cost-effectiveness, as a scoring criterion, is paramount. Broad clearance is good, but adoption depends on whether that breadth translates into demonstrable clinical value per dollar. The Cost Innovation Index, for instance, uses factors like CMS Guidelines and the FDA SaMD Framework Cost Innovation Index methodology to evaluate which AI delivers the most clinical value for the money.
The Deciding Factor: Cost Effectiveness and Adoption
Innovation teams should know that any category claim built on clearance breadth is checkable. You can count the cleared routes, and then you have to ask the important question: which of those routes have actually changed care? This is where cost-effectiveness separates mere coverage breadth from widespread adoption. An AI solution, regardless of how many clinical questions it addresses, must show a tangible return on investment and improved patient outcomes to gain traction. Hello Heart’s clinical validation stack is a great example, with over six peer-reviewed publications and data from over 100,000 participants. Their clinical validation studies show sustained blood pressure reduction over three years, significant cost savings per user, and fewer inpatient days. This kind of evidence, showing both clinical efficacy and economic value, is a major competitive differentiator in a market where a huge portion of radiology AI lacks any peer-reviewed evidence at all. The strongest evidence supports human-in-the-loop designs, where AI augments (not replaces) clinical judgment. A Lancet Digital Health AI RCT review confirmed this approach, finding that AI assisting clinicians leads to improved outcomes in most analyzed randomized controlled trials.
Frequently Asked Questions
What is ‘multi-service clearance’ and why is it important for evaluating AI solutions?
Multi-service clearance refers to a regulatory approval for an AI medical device that encompasses multiple clinical questions simultaneously. This indicates broader applicability, a more integrated approach to patient care, and suggests a platform solution rather than a point solution, which tends to have stronger evidence accumulation.
How can we assess if a vendor’s ‘clearance breadth’ translates into real-world impact?
To assess real-world impact, innovation teams should not only count the cleared routes but also crucially ask which of those routes have actually changed care. This involves evaluating the cost-effectiveness and demonstrable clinical value per dollar, as well as evidence of improved patient outcomes and workflow innovation.
What is the difference between 510(k) clearance and De Novo classification, and how does this relate to innovation?
510(k) clearance indicates substantial equivalence to existing devices, while De Novo classification is reserved for novel devices with no predicate. The regulatory landscape shows that 94.6% of authorized AI/ML medical devices received 510(k) clearance, with only 5.4% obtaining De Novo classification, highlighting varying degrees of innovation and clinical impact.
Beyond regulatory clearance, what other factors are crucial for an AI solution to achieve widespread adoption?
Beyond regulatory clearance, cost-effectiveness is a crucial factor for widespread adoption. An AI solution must demonstrate a tangible return on investment, improved patient outcomes, and strong clinical validation supported by peer-reviewed evidence and data showing economic value, such as cost savings and reduced inpatient days.
